Currently, various drugs that inhibit the activity of the JAK/STAT3 pathway or SETD2-targeted drugs are in the research and development stage or clinical trials, and some have been proven to have antitumor activity against various subtypes of peripheral T-cell lymphomas (31, 32). The gene discussed is SETD2; the disease is peripheral T-cell lymphoma, not otherwise specified.